64 results about "Variant form" patented technology

A method for dynamically discriminating a program code patch update after merging a patch file into unmodified source code for dynamic review. The method includes providing a graphical user interface (GUI) to enable a user to merge a source code patch file into an existing, pre-modified version of source code to generate a variant form of the existing, pre-modified source code and binary artifacts, via the GUI, presenting a display image highlighting differences between existing, pre-modified source code and the variant form after merging the source code patch file into the existing, pre-modified source code, via the GUI, presenting the user with an option of debugging the existing, pre-modified version of the source code, the GUI presenting linked views highlighting the existing, pre-modified version of the source code with the variant form of the source code, in parallel, debugging the variant form of the source code, the GUI presenting linked views highlighting the existing, pre-modified version with the variant form of the source code, in parallel and debugging both the existing, pre-modified version of the source code and the variant form of the source code, in parallel, while stepping through the existing, pre-modified and variant forms of the source code synchronously, while the GUI presents the linked views.

The present invention relates to a variant form of the receptor for the obese gene product. In particular, the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals. In addition, it relates to methods of inhibiting or down-regulating expression of this variant in cells to augment their responsiveness to weight regulation by leptin as well as methods of using compounds to directly activate signal transduction pathways associated with this ligand-receptor system.

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and / or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and / or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

The present invention relates to variant forms of human prolactin which act as antagonists at the prolactin receptor, and to the use of such variants in the treatment of human cancers and proliferative disorders, including both benign and malignant diseases of the breast and prostate.

The present invention relates to variant forms of human prolactin which act as antagonists at the prolactin receptor, and to the use of such variants in the treatment of human cancers and proliferative disorders, including both benign and malignant diseases of the breast and prostate.

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and / or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

The present invention provides cyclopropane fatty acid synthase genes and proteins, and methods of their use. The present invention encompasses both native and recombinant wild-type forms of the synthase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type synthase. The present invention also provides methods of using cyclopropane fatty acid synthase genes and proteins, including in their expression in transgenic organisms and in the production of cyclopropane fatty acids in plant oils, and in particular seed oils.

The present invention relates to divinyl ether synthase genes, proteins, and methods of their use. The present invention encompasses both native and recombinant wild-type forms of the synthase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type synthase. The present invention also relates to methods of using divinyl ether synthase genes and proteins, including in their expression in transgenic organisms and in the production of divinyl ether fatty acids, and to methods of suing divinyl ether fatty acids, including in the protection of plants from pathogens.

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and / or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

The present invention relates to diacylglycerol acyltransferase genes and proteins, and methods of their use. In particular, the invention describes genes and proteins that exhibit both long-chain acyltransferase and acetyltransferase activity. The present invention encompasses both native and recombinant wild-type forms of the transferase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type transferase. The present invention also relates to methods of using diacylglycerol acyltransferase genes and proteins, including in their expression in transgenic organisms and in the production of acetyl-glycerides in plant oils, and in particular seed oils.

The invention relates to recombinant expression of variant forms of C1 CBH1a and homologs thereof, having improved thermostability, low-pH tolerance, specific activity and other desirable properties. Also provided are methods for producing ethanol and other valuable organic compounds by combining cellobiohydrolase variants with cellulosic materials.

Systemic administration of azithromycin for a period of at least two weeks is effective in ameliorating the signs and symptoms of granulomatous rosacea, a variant form of rosacea that often fails to respond favorably to treatment regimens that are effective against forms of rosacea other than granulomatous rosacea.

The present invention relates to diacylglycerol acyltransferase genes and proteins, and methods of their use. In particular, the invention describes genes and proteins that exhibit both long-chain acyltransferase and acetyltransferase activity. The present invention encompasses both native and recombinant wild-type forms of the transferase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type transferase. The present invention also relates to methods of using diacylglycerol acyltransferase genes and proteins, including in their expression in transgenic organisms and in the production of acetyl-glycerides in plant oils, and in particular seed oils.

The invention relates to a sampler for sampling sediment suspended in fluid, the sampler including a container and a closure. The container includes an opening through which fluid can enter and be contained therein. The closure is associated with the opening of the container and includes a moveable part which on tipping or inversion of the sampler moves between an open and a closed position. In use in the open position the sample can enter the container through the opening and be contained therein, and in the closed position fluid in the container is substantially prevented from leaving the container. The invention also relates to variant forms of the invention and a method of use.

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Methods for the treatment of coagulation disorders using Factor V / Va variants are provided.

The invention relates to a sputtering target and the preparation method thereof, wherein the sputtering target comprises a matrix material containing a first oxide of high refractive index and metallic components. The first oxide is selected from the group composed of titanium oxides of any variant forms, niobium oxides of any variant forms, vanadium oxides of any variant forms, yttrium oxides of any variant forms, molybdenum oxides of any variant forms, zirconium oxides of any variant forms, tantalum oxides of any variant forms, tungsten oxides of any variant forms, hafnium oxides of any variant forms, and the mixture thereof. The composition also contains a second oxide is selected from the group composed of lanthanides oxides of any variant forms, scandium oxides of any variant forms, and lanthanum oxides of any variant forms. The matrix material has apertures, and the sputtering target is applied for sputtering under high power density.

The invention discloses a method for processing the conversion of variant forms of Unicode four-byte code-containing East-Asia expression ideographs in search engines. According to a table of variant forms of Chinese characters, the method adopts the idea of layered matching and realizes the matched search of variant forms of characters between various East-Asia Chinese characters, between the current frequently used characters and ancient writings and between ancient writings of different versions in the search engines. As searching, as long as any one of the variant forms of characters is inputted, the information containing other variant forms of characters will be searched. The invention makes the search engines able to more accurately search the user-needed information without considering the conversion problem between various variant forms of characters.

The invention discloses a method for immobilizing human source arginase-1 through surface display. The method comprises the steps of adding signal peptide and charged polypeptide to the amino terminal of a protein cleavage variant (InaK-N) formed on an ice core, fusing human source arginase-1 into the carboxyl terminal, and designing an HA label at the carboxyl terminal; constructing various recombinant plasmids to convert competent escherichia coli cells, so that different genetic engineering strains are obtained; conducting shake-flask culture on the strains; detecting the display efficiency and enzyme activity of human source arginase-1; selecting the strain with the highest enzyme activity for mass culture, conducting efficient L-arginine conversion, and synthesizing L-ornithine. Human source arginase-1 fused in the protein cleavage variant formed on the ice core is effectively displayed on the surface of an escherichia coli cell, so that human source arginase-1 is immobilized. Compared with an original ice core protein display system, the method has the advantage that the display efficiency and enzyme activity of human source arginase-1 are improved remarkably. Compared with a chitin immobilizing method, the method has the advantages that cost is reduced, process is shortened, and purification steps are simplified.

The invention discloses a computer network anomaly detection method and system and a mobile terminal in the technical field of network security. The detection method includes the following specific steps: S1, monitoring and analyzing activities of a user and a system; S2, checking system configuration and bugs; S3, identifying known attacks and sending an alarm to the relevant personnel; S4, performing statistical analysis on daily behaviors of the user and the system; S5, evaluating the integrity of important systems and data; and S6, operating system log management, and identifying the useractivities that violate security policies. According to the scheme of the invention, the detection system is arranged on each node of the network, so that attackers cannot easily transfer evidences, strong detection real-time performance can be achieved, the possibility of the own attacks can be reduced, and meanwhile, by adopting the high learning and adaptive capabilities of a neural network, new intrusion behavior features can be identified with high accuracy, and the new intrusion behavior features and variant forms of the known intrusion behaviors can also be identified with a certain probability.

The invention discloses Mongolian coding technology adopting alphabetic variant forms. During establishing a computer Mongolian coded set of all alphabetic variant forms, coding is carried out according to the following rules: coding letters of different pronunciations according to the pronunciation order in the state-standardized Mongolian Alphabetic Order; coding the variant forms of letters of identical pronunciations according to different positions in words, namely the order of independent font, prefix font, suffix font and stem font in turn; and coding the variant forms of letters with identical pronunciations and identical stem positions. The Mongolian coding technology has the advantages that the technology completely realizes pronunciation coding of all Mongolian and natural ordering of Mongolian words; meanwhile, the technology completely realizes mutual conversion between Mongolian words and Latin as well as one-to-many and many-to-one relation of ISO / IEC 10646 mutual conversion; moreover, the technology provides loose design and manufacture conditions for the development of Mongolian fonts used in computers, and solves the technical bottleneck in Mongolian speech input and output.

The present invention relates to novel diacylglycerol acyltransferase genes and proteins, and methods of their use. In particular, the invention describes genes encoding proteins having diacylglycerol acetyltransferase activity, specifically for transferring an acetyl group to a diacylglycerol substrate to form acetyl-Triacylglycerols (ac-TAGS), for example, a 3-acetyl-1,2-diacyl-sn-glycerol. The present invention encompasses both native and recombinant wild-type forms of the transferase, as well as mutants and variant forms. The present invention also relates to methods of using novel diacylglycerol acyltransferase genes and proteins, including their expression in transgenic organisms at commercially viable levels, for increasing production of 3-acetyl-1,2-diacyl-sn-glycerols in plant oils and altering the composition of oils produced by microorganisms, such as yeast, by increasing ac-TAG production. Additionally, oils produced by methods of the present inventions comprising genes and proteins are contemplated for use as biodiesel fuel, in polymer production and as naturally produced food oils with reduced calories.